Morgan Stanley Maintains Overweight Rating on Pharmassset

A report from Morgan Stanley reiterates its Overweight rating on Pharmasset VRUS. The report states, “We are attending the American Association of the Study of Liver Disease Annual Meeting where data from the ELECTRON study, examining 12 wks of PSI-7977 + ribavirin (R) + variable interferon (IFN) durations of 0-12 wks, were presented. Our overall takeaway from these data, in conjunction with existing ‘7977 data, is that Pharmasset's 2nd gen nuke retains its potential best in disease profile on the important metrics to us and physicians: efficacy, safety, tolerability, resistance, and pan-genotype activity." VRUS closed Friday at $68.89.